[go: up one dir, main page]

WO2012054564A3 - Anti-vegf antibody/fragment conjugated gold nanoparticles, and fabrication and therapeutic methods - Google Patents

Anti-vegf antibody/fragment conjugated gold nanoparticles, and fabrication and therapeutic methods Download PDF

Info

Publication number
WO2012054564A3
WO2012054564A3 PCT/US2011/056825 US2011056825W WO2012054564A3 WO 2012054564 A3 WO2012054564 A3 WO 2012054564A3 US 2011056825 W US2011056825 W US 2011056825W WO 2012054564 A3 WO2012054564 A3 WO 2012054564A3
Authority
WO
WIPO (PCT)
Prior art keywords
gold nanoparticles
vegf antibody
therapeutic methods
derived therefrom
fabrication
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/056825
Other languages
French (fr)
Other versions
WO2012054564A2 (en
Inventor
Ravi Shukla
Dean P. Hainsworth
Kattesh V. Katti
Raghuraman Kannan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Missouri Columbia
University of Missouri St Louis
Original Assignee
University of Missouri Columbia
University of Missouri St Louis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Missouri Columbia, University of Missouri St Louis filed Critical University of Missouri Columbia
Publication of WO2012054564A2 publication Critical patent/WO2012054564A2/en
Publication of WO2012054564A3 publication Critical patent/WO2012054564A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Ceramic Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Preferred embodiments of the invention include gold nanoparticles, preferably less than about 20nm, that are conjugated with biologically active anti- VEGF antibody or a fragment derived therefrom. The particles can be formed by a "one-pot" synthesis method of the invention, in which the biologically active anti-VEGF antibody or a fragment derived therefrom acts to stabilize formed gold nanoparticles while simultaneously retaining biological activity. The method uses a reducing agent of nontoxic trimeric alanine compound that is benign toward the biological activity of the anti-VEGF antibody or a fragment derived therefrom. Therapeutic methods of the invention include injection of a solution of conjugated gold nanoparticles of the invention at vascularisation sites such as cancer sites and intraocular injection.
PCT/US2011/056825 2010-10-19 2011-10-19 Anti-vegf antibody/fragment conjugated gold nanoparticles, and fabrication and therapeutic methods Ceased WO2012054564A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45532210P 2010-10-19 2010-10-19
US61/455,322 2010-10-19

Publications (2)

Publication Number Publication Date
WO2012054564A2 WO2012054564A2 (en) 2012-04-26
WO2012054564A3 true WO2012054564A3 (en) 2012-07-05

Family

ID=45975851

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/056825 Ceased WO2012054564A2 (en) 2010-10-19 2011-10-19 Anti-vegf antibody/fragment conjugated gold nanoparticles, and fabrication and therapeutic methods

Country Status (1)

Country Link
WO (1) WO2012054564A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108348544B (en) * 2015-07-13 2021-01-22 首尔大学校产学协力团 Composition for inhibiting angiogenesis containing nanoparticle-vitreous protein complex as active ingredient and use thereof

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015168619A1 (en) * 2014-05-02 2015-11-05 Mayo Foundation For Medical Education And Research Individualized treatment of eye disease
US20190336613A1 (en) * 2016-09-21 2019-11-07 Mayo Foundation For Medical Education And Research Compositions to treat ultraviolet (uv)-induced skin injury

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030118657A1 (en) * 2001-12-04 2003-06-26 West Jennifer L. Treatment of disease states characterized by excessive or inappropriate angiogenesis
US20060222595A1 (en) * 2005-03-31 2006-10-05 Priyabrata Mukherjee Nanoparticles for therapeutic and diagnostic applications
US20100104652A1 (en) * 2008-10-27 2010-04-29 University Of Arkansas Use of advanced nanomaterials for increasing sepecific cell functions
US20100183728A1 (en) * 2007-03-07 2010-07-22 Desai Neil P Nanoparticle comprising rapamycin and albumin as anticancer agent

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030118657A1 (en) * 2001-12-04 2003-06-26 West Jennifer L. Treatment of disease states characterized by excessive or inappropriate angiogenesis
US20060222595A1 (en) * 2005-03-31 2006-10-05 Priyabrata Mukherjee Nanoparticles for therapeutic and diagnostic applications
US20100183728A1 (en) * 2007-03-07 2010-07-22 Desai Neil P Nanoparticle comprising rapamycin and albumin as anticancer agent
US20100104652A1 (en) * 2008-10-27 2010-04-29 University Of Arkansas Use of advanced nanomaterials for increasing sepecific cell functions

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108348544B (en) * 2015-07-13 2021-01-22 首尔大学校产学协力团 Composition for inhibiting angiogenesis containing nanoparticle-vitreous protein complex as active ingredient and use thereof

Also Published As

Publication number Publication date
WO2012054564A2 (en) 2012-04-26

Similar Documents

Publication Publication Date Title
WO2011084808A3 (en) Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
MX2009005727A (en) Amphiphilic entity nanoparticles.
WO2010059253A3 (en) Methods and compositions for localized agent delivery
WO2007047291A3 (en) Anti-glypican-3 antibody
MX2011010673A (en) Nanoparticle formulations and uses therof.
WO2007073486A3 (en) Methods and compositions for delivering active agents with enhanced pharmacological properties
WO2009109927A3 (en) Glp-1 receptor agonists and related active pharmaceutical ingredients for treatment of cancer
WO2008030818A3 (en) Novel liposome compositions
WO2009063970A1 (en) Diagnosis and treatment of cancer using anti-gpr49 antibody
WO2011069104A3 (en) Multispecific antibodies, antibody analogs, compositions, and methods
WO2007067682A3 (en) In vivo cell surface engineering
WO2007134245A3 (en) Elastin-like polymer delivery vehicles
WO2009114614A3 (en) Compositions and methods for controlled delivery of inhibitory ribonucleic acids
WO2005089106A3 (en) Degradable nanoparticles
WO2011035335A3 (en) Stabilized liquid and lyophilized adamts13 formulations
MX2009006088A (en) Nanoemulsion.
WO2010100200A3 (en) Lyophilised antibody formulation
WO2010078421A8 (en) Substituted 5,6-dihydro-6-phenylbenzo[f] isoquinolin-2-amine compounds
SG10201407281UA (en) Specific binding proteins and uses thereof
WO2009135855A3 (en) Encapsulation of biologically active agents
WO2013006743A3 (en) Personal care compositions with improved solubility of a solid cosmetic active substance
WO2008010991A3 (en) Methods and compositions for the treatment of cancer
EP3450459A3 (en) Anti-cdh3 antibodies and uses thereof
WO2008012399A3 (en) Novel compositions of fungal inocula, method for the preparation thereof and use thereof for improving the growth of cultures
WO2015095354A3 (en) Compositions and methods for treating fatty tissue buildup

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11835041

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11835041

Country of ref document: EP

Kind code of ref document: A2